TY - JOUR
T1 - Characterisation of antithrombin-dependent anticoagulants through clot waveform analysis to potentially distinguish them from antithrombin-independent inhibitors targeting activated coagulation factors
AU - Wakui, Masatoshi
AU - Fujimori, Yuta
AU - Nakamura, Shoko
AU - Oka, Shusaku
AU - Ozaki, Yuko
AU - Kondo, Yoshino
AU - Nakagawa, Terumichi
AU - Katagiri, Hisako
AU - Murata, Mitsuru
N1 - Funding Information:
Funding This work was supported by the BMS/Pfizer Japan Thrombosis Investigator Initiated Research Program (JRISTA). YF was supported by a grant from the Charitable Trust Laboratory Medicine Research Foundation of Japan.
Funding Information:
Competing interests The BMS/Pfizer Japan Thrombosis Investigator Initiated Research Program (JRISTA), which supported this work, is administered by the companies, Bristol-Myers Squibb and Pfizer.
Publisher Copyright:
© 2021 The Author(s). Published by Cambridge University Press.
PY - 2021/4/1
Y1 - 2021/4/1
N2 - Aims While antithrombin (AT)-independent inhibitors targeting thrombin or activated factor X have been assessed through clot waveform (CWA), there are no reports on assessment with respect to AT-dependent anticoagulants. The present study aims to characterise AT-dependent anticoagulants through CWA to distinguish them from AT-independent inhibitors. Methods CWA was applied to the activated partial thromboplastin time (APTT) assay of plasma samples spiked with each of AT-dependent drugs (unfractionated heparin, enoxaparin and fondaparinux) and AT-independent drugs (rivaroxaban, apixaban, edoxaban, dabigatran, argatroban, hirudin and bivalirudin), which was performed using the CS-5100 or CN-6000 (Sysmex). The APTT-CWA data were automatically gained by the analyser program. The positive mode of clotting reaction curves was defined as the direction towards fibrin generation. Results Regarding dose-response curves in AT-dependent anticoagulants, the maximum positive values of the first and secondary derivatives (Max1 and Max p 2, respectively) and the maximum negative values of the secondary derivative (Max n 2) seemed to drop to zero without making an asymptotic line, consistent with the irreversibility. Such a feature was observed also in hirudin, as reported previously. Notably, the symmetric property of Max1 peaks in the waveforms was distorted dose dependently in AT independent but not AT-dependent drugs. A plot of Max p 2 logarithm versus Max n 2 logarithm was linear. The slope was about 1 in AT-dependent drugs while that was more than 1 in AT-independent drugs. These features made it possible to distinguish AT-dependent and AT-independent drugs. Conclusions The results aid in further understanding of the pharmacological aspects of anticoagulation and in screening of candidates for novel anticoagulants.
AB - Aims While antithrombin (AT)-independent inhibitors targeting thrombin or activated factor X have been assessed through clot waveform (CWA), there are no reports on assessment with respect to AT-dependent anticoagulants. The present study aims to characterise AT-dependent anticoagulants through CWA to distinguish them from AT-independent inhibitors. Methods CWA was applied to the activated partial thromboplastin time (APTT) assay of plasma samples spiked with each of AT-dependent drugs (unfractionated heparin, enoxaparin and fondaparinux) and AT-independent drugs (rivaroxaban, apixaban, edoxaban, dabigatran, argatroban, hirudin and bivalirudin), which was performed using the CS-5100 or CN-6000 (Sysmex). The APTT-CWA data were automatically gained by the analyser program. The positive mode of clotting reaction curves was defined as the direction towards fibrin generation. Results Regarding dose-response curves in AT-dependent anticoagulants, the maximum positive values of the first and secondary derivatives (Max1 and Max p 2, respectively) and the maximum negative values of the secondary derivative (Max n 2) seemed to drop to zero without making an asymptotic line, consistent with the irreversibility. Such a feature was observed also in hirudin, as reported previously. Notably, the symmetric property of Max1 peaks in the waveforms was distorted dose dependently in AT independent but not AT-dependent drugs. A plot of Max p 2 logarithm versus Max n 2 logarithm was linear. The slope was about 1 in AT-dependent drugs while that was more than 1 in AT-independent drugs. These features made it possible to distinguish AT-dependent and AT-independent drugs. Conclusions The results aid in further understanding of the pharmacological aspects of anticoagulation and in screening of candidates for novel anticoagulants.
KW - anticoagulants
KW - blood coagulation
KW - haematology
KW - thrombosis
UR - http://www.scopus.com/inward/record.url?scp=85094593629&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094593629&partnerID=8YFLogxK
U2 - 10.1136/jclinpath-2020-206835
DO - 10.1136/jclinpath-2020-206835
M3 - Article
C2 - 32796051
AN - SCOPUS:85094593629
SN - 0021-9746
VL - 74
SP - 251
EP - 256
JO - Journal of Clinical Pathology
JF - Journal of Clinical Pathology
IS - 4
ER -